...
首页> 外文期刊>Organic process research & development >Toward a Scalable Synthesis and Process for EMA401, Part I: Late Stage Process Development, Route Scouting, and ICH M7 Assessment
【24h】

Toward a Scalable Synthesis and Process for EMA401, Part I: Late Stage Process Development, Route Scouting, and ICH M7 Assessment

机译:对EMA401的可扩展合成和过程,第一部分:晚期过程开发,路径侦察和ICH M7评估

获取原文
获取原文并翻译 | 示例

摘要

We present the enantioselective synthesis of sodium (3S)-5-(benzyloxy)-2-(diphenylacetyI)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (EMA401, olodanrigan), an angiotensin II type 2 antagonist. The manuscript features the process optimizations of the end game used for late phase clinical supplies, an overview of synthetic strategies identified in a route scouting exercise to a key intermediate phenylalanine derivative, and the analytical control strategy of the potentially formed highly toxic impurity bis(chloromethyl) ether (BCME). Starting from the phenylalanine derivative, we describe the optimizations of the end game from early phase to late phase processes with consequent improvements in the PMI factor. This sequence includes a Pictet-Spengler cyclization and an amide coupling as the last bond-forming steps, and the manufacturing process was successfully implemented on a 175 kg scale in a pilot plant setup. The modified process conditions eliminated one step by in situ activation of the carboxylic acid, avoided the REACH listed solvent DMF, and resulted in a PMI improvement by a factor of 3. In the final crystallization, a new, thermodynamically more stable modification of the drug substance was found in the complex solid-state landscape of EMA401 during an extensive polymorph screening. A process suitable for large-scale production was developed to prepare the new polymorph, avoiding the need of any special equipment such as fluidized bed drying required in the early phase process. In the second section, some of the synthetic approaches investigated for the route scouting of the phenylalanine derivative key intermediate are presented. To conclude, we discuss the analytical control strategy for BCME, the formation of which, due to the simultaneous presence of HCI and CH2O in the Pictet-Spengler cyclization, could not be ruled out. The BCME purge factor calculations using the tools of ICH M7 control option 4 are compared to actual results from spiking experiments.
机译:我们介绍了钠(3S)-5-(苄氧基)-2-(二苯基酰基)-6-甲氧基-1,2,3,4-四氢异喹啉-3-羧酸盐(EMA401,olodanrigan),一种血管紧张素II型的映选择性合成2个拮抗剂。该手稿具有用于晚期临床用品的结束游戏的过程优化,概述了在路径侦察锻炼中鉴定的合成策略,以关键中间苯丙氨酸衍生物,以及潜在形成的高毒杂质双(氯甲基)的分析控制策略)乙醚(BCME)。从苯丙氨酸衍生物开始,我们将最终游戏从早期阶段到后期过程的优化描述,随后PMI因子的改进。该序列包括像上次结合成步骤的Pictet-Spengler环化和酰胺耦合,并且在先导设备设置中成功地在175kg刻度上成功地实现了制造过程。改性工艺条件通过原位活化消除了羧酸的逐步,避免了达到的溶剂DMF,并导致PMI改善3.在最终结晶,新的,热力学上更稳定的药物改性在广泛的多晶型筛选期间,在EMA401的复杂固态景观中发现了物质。开发了一种适用于大规模生产的过程以制备新的多晶型物,避免了早期过程中需要采用任何特殊设备的特殊设备,例如流化床干燥。在第二部分中,提出了用于苯丙氨酸衍生物关键中间体的路径侦察的一些合成方法。为了得出结论,讨论BCME的分析控制策略,由于HCI和CH2O在Pictet-Spengler环状中的同时存在,因此无法排除所形成的。使用ICH M7控制选项4的工具的BCME吹扫因子计算与尖峰实验的实际结果进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号